Home › Funds › MFS Investment Management › RXRX
MFS Investment Management position in RXRX
RECURSION PHARMACEUTICALS IN · Health Care
Latest position (Q3 2022)950.59K sh
Reported value held$10.11M
Portfolio Weight0.00%
First reportedQ2 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2021 | 975.93K | $35.62M | New |
| Q3 2021 | 895.86K | $20.61M | Reduce |
| Q4 2021 | 1.30M | $22.27M | Add |
| Q2 2022 | 1.33M | $10.80M | Add |
| Q3 2022 | 950.59K | $10.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding RXRX
- Vanguard Group 47.19M sh · $193.00M · Q4 2025
- BlackRock Inc 50.30M sh · $184.62M · Q2 2026
- ARK Invest 41.34M sh · $151.71M · Q2 2026
- Baillie Gifford & Co 23.49M sh · $86.20M · Q2 2026
- Geode Capital Management 13.82M sh · $50.72M · Q2 2026
- UBS Group AG 8.95M sh · $32.84M · Q2 2026
- Norges Bank Investment Management 6.83M sh · $25.08M · Q2 2026
- Northern Trust Corp 4.76M sh · $17.46M · Q2 2026
- Marshall Wace 4.71M sh · $17.30M · Q2 2026
- Charles Schwab Investment Management 4.14M sh · $15.19M · Q2 2026
- Goldman Sachs Group 3.92M sh · $14.38M · Q2 2026
- Two Sigma Investments 3.35M sh · $12.31M · Q2 2026